97 related articles for article (PubMed ID: 8441028)
1. Influence of dose selection on absorbed dose profiles in radioiodine treatment of diffuse toxic goiters in patients receiving or not receiving carbimazole.
Clerc J; Izembart M; Dagousset F; Jaïs JP; Heshmati HM; Chevalier A; Léger AF; Barritault L
J Nucl Med; 1993 Mar; 34(3):387-93. PubMed ID: 8441028
[TBL] [Abstract][Full Text] [Related]
2. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
[TBL] [Abstract][Full Text] [Related]
3. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
[TBL] [Abstract][Full Text] [Related]
4. Radioiodine therapy and thyrostatic drugs and iodine.
Moka D; Dietlein M; Schicha H
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S486-91. PubMed ID: 12192550
[TBL] [Abstract][Full Text] [Related]
5. Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: results from continuous dose-effect models.
Walter MA; Schindler C; Christ-Crain M; Müller-Brand J; Müller B
Eur J Clin Invest; 2009 Jan; 39(1):51-7. PubMed ID: 19087129
[TBL] [Abstract][Full Text] [Related]
6. Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism.
El Refaei SM; Shawkat W
Nucl Med Commun; 2008 Jul; 29(7):642-8. PubMed ID: 18528187
[TBL] [Abstract][Full Text] [Related]
7. [Radioiodine therapy of Graves' disease--a dosimetric comparison of various therapy regimens of antithyroid agents].
Urbannek V; Voth E; Moka D; Schicha H
Nuklearmedizin; 2001 Aug; 40(4):111-5. PubMed ID: 11556200
[TBL] [Abstract][Full Text] [Related]
8. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
Berg GE; Michanek AM; Holmberg EC; Fink M
J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
[TBL] [Abstract][Full Text] [Related]
9. Early treatment with low fixed dose (5 mCi) radioiodine therapy is effective in Indian subjects with Graves' disease.
Sanyal D; Mukhhopadhyay P; Pandit K; Chatterjee J; Raychaudhuri M; Mukherjee S; Chowdhury S
J Indian Med Assoc; 2008 Jun; 106(6):360-1, 372. PubMed ID: 18839646
[TBL] [Abstract][Full Text] [Related]
10. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
[TBL] [Abstract][Full Text] [Related]
11. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
Howarth D; Epstein M; Lan L; Tan P; Booker J
Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
[TBL] [Abstract][Full Text] [Related]
12. Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication.
Sabri O; Zimny M; Schulz G; Schreckenberger M; Reinartz P; Willmes K; Buell U
J Clin Endocrinol Metab; 1999 Apr; 84(4):1229-33. PubMed ID: 10199759
[TBL] [Abstract][Full Text] [Related]
13. Radioiodine therapy of the autonomous thyroid nodule in patients with or without visible extranodular activity.
Clerc J; Dagousset F; Izembart M; Jais JP; Heshmati HM; Alcaïs A; Chevalier A; Léger AF; Barritault L
J Nucl Med; 1995 Feb; 36(2):217-23. PubMed ID: 7830117
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
Bakker SC; Zanin DE; Zweers EJ
Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
[TBL] [Abstract][Full Text] [Related]
16. [Determination of factors affecting the therapeutic outcome of radioiodine therapy in patients with Graves' disease].
Sabri O; Schulz G; Zimny M; Schreckenberger M; Zimny D; Wagenknecht G; Kaiser HJ; Dohmen BM; Bares R; Büll U
Nuklearmedizin; 1998 May; 37(3):83-9. PubMed ID: 9604227
[TBL] [Abstract][Full Text] [Related]
17. Time course to hypothyroidism after fixed-dose radioablation therapy of Graves' disease in children.
Nebesio TD; Siddiqui AR; Pescovitz OH; Eugster EA
J Pediatr; 2002 Jul; 141(1):99-103. PubMed ID: 12091858
[TBL] [Abstract][Full Text] [Related]
18. [Thyroid diseases in sub-Saharan Africa].
Sidibé el H
Sante; 2007; 17(1):33-9. PubMed ID: 17897900
[TBL] [Abstract][Full Text] [Related]
19. The effect of carbimazole following radioiodine therapy on radiation dose to the thyroid.
Gimlette TM; Kocak R; Herbert RG; Squire CR
Nuklearmedizin; 1981 Apr; 20(2):72-5. PubMed ID: 6165965
[TBL] [Abstract][Full Text] [Related]
20. Low-dosage 131-I therapy of thyrotoxicosis (diffuse goiters). A five-year follow-up study.
Cevallos JL; Hagen GA; Maloof F; Chapman EM
N Engl J Med; 1974 Jan; 290(3):141-3. PubMed ID: 4859623
[No Abstract] [Full Text] [Related]
[Next] [New Search]